Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2002-03-19
2009-12-01
Yaen, Christopher H (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reexamination Certificate
active
07625558
ABSTRACT:
Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise adminstering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed.
REFERENCES:
patent: 5200178 (1993-04-01), Strauss et al.
patent: 5367060 (1994-11-01), Vandlen et al.
patent: 5464751 (1995-11-01), Greene et al.
patent: 5470571 (1995-11-01), Herlyn et al.
patent: 5663144 (1997-09-01), Greene et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5705157 (1998-01-01), Greene
patent: 5707618 (1998-01-01), Armentano et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5756283 (1998-05-01), Wilson et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5824311 (1998-10-01), Greene et al.
patent: 5837523 (1998-11-01), Greene et al.
patent: 6027892 (2000-02-01), Chang et al.
patent: 6100377 (2000-08-01), Greene
patent: 0359282 (1990-03-01), None
patent: A0616812 (1994-09-01), None
patent: WO-8906692 (1989-07-01), None
patent: WO-9314781 (1993-08-01), None
patent: WO-9321232 (1993-10-01), None
patent: WO 94/22478 (1994-10-01), None
patent: WO-9520045 (1995-07-01), None
patent: WO 95/30331 (1995-11-01), None
patent: WO 95/34312 (1995-12-01), None
patent: WO 96/34312 (1996-10-01), None
patent: WO 96/34617 (1996-11-01), None
patent: WO 96/39530 (1996-12-01), None
patent: WO-9640210 (1996-12-01), None
patent: WO-9735885 (1997-10-01), None
patent: WO-9802540 (1998-01-01), None
patent: WO-9817797 (1998-04-01), None
patent: WO-9818489 (1998-05-01), None
patent: WO 99/44645 (1999-09-01), None
patent: WO-9960023 (1999-11-01), None
patent: WO-9931140 (2000-09-01), None
Heldin, C., Cell, 80: 213-223, 1995.
Baselga, J. et al., Breast Cancer Research and Treatment, 29: 127-138, 1994.
Schmidt-Ullrich, R.K. et al. Oncogene, 15: 1191-1197, 1997.
Balaban et al (Biochim. Biophys. Acta. 1996; 1314(1-2):147-156).
Goldman R et al (Biochemistry 1990 ; 29(50) :11024-11028).
Arteaga CL, et al., p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Jul. 15, 1994;54(14):3758-65. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd+Retrieve&db+pubmed&dopt-abstract . . . (May 31, 2006).
Arteaga Carlos L., et al., p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Jul. 15, 1994;54(14):3758-65.
Bergman, et al. Radioresistance, Chemoresistance and Apoptosis Resistance.38 Radiation Oncology Vo. 27 No. 1, Jan. 1997, pp. 47-57.
Christen, et al. “Epidermal Growth Factor Regulates the in Vitro Sensitivity of Human Ovarian Carcinoma Cells to Cisplatin” THe American Society for Clinical Investigation, Inc., vol. 86, Nov. 1990, (pp. 1632-1640).
Dougall et al. “Association of Signaling Proteins with a Nonmitogenic Heterodimeric Complex Composed of Epidermal Growth Factor Receptor and Kinase-Inactive p185c-neu”, DNA and Cell Biology, vol. 15, Nov. 1, 1996, Mary An Liebert, Inc. (pp. 31-40).
Earp, et al. : Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat. Jul. 1995;35(1):115-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt-abstract...(May 31, 2006).
Earp, et al. :Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat. 1995;115-132.
Goldkorn, et al. “EGF receptor phosphorylation is affected by ionizing radition.” Biochim Biophys Acta. Oct. 11, 1997;1358(3):289-99. http://www.ncbi
lm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt-abstract...(May 31, 2006).
Goldstein et al. FDA Review Team, “Herceptin® Trastuzumab” Genentech, Inc. Sep. 25, 1998 (pp. 1-99).
Heidin, “Dimerization of Cell Surface Receptors in Signal Transduction” Cell Press, vol. 80, Jan. 27, 1995, pp. 213-223.
Hudziak et al. “p185HER2Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor”, Molecular and Cellular Biology, Mar. 1989, pp. 1165-1172.
Kroizman et al. “Heterodimerization of c-erbB2 with Different Epidermal Growth Factor Receptor Mutants Elicits Stiumlatory or Inhibitory Responses” The Journal of Biological Chemistry vol. 267, No. 12, Apr. 25, 1992, pp. 8056-8063.
Liang et al. “Sensitization of breast cancer cells to radiation by trastuzumab”, Mol Cancer ther. 2003; 2 pages 1113-1120.
Lichtenstein et al. Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2
eu oncogenes. Cancer Res. Nov. 15, 1990; 50(20):7364-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt-abstract . . . (May 31, 2006).
Lichtenstein et al. Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2
euoncogenes. Cancer Res. Nov. 15, 1990; 50(20):7364-70.
Pegram, et al. “The effect of HER-2
eu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells”, Oncogene, (1997) 15, pp. 537-547.
Petit, et al. Neutralizing Antibodies against Epidermal Growth Factor and ErbB-2
eu Receptor Tyrosine Kinases Down-Regulate Vascular Endothelial Growth Factor Production by Tumor Cells in Vitro and in Vivo, The American Journal of Pathology, Dec. 1997; 151 6; Health Medicine Complete pp. 1523-1530.
Pietras, et al. “New Radiation Therapy for HER-2-overexpressing Breast Cancer” Breast Cancer Research program, http://www.cbcrp.org/research/pagegrant.asp?grant—id=1696. May 31, 2006 5 pages.
Pietras, et al. “Antibody to HER-2
eu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.” Oncogene, Jul. 1994 (7): pp. 1829-1838.
Pietras et al. “Monoclonal Antibody to HER/-2neuReceptor Modulates Repair of Radiation-induced DNA Damage and Enhances Radiosensitivity of Human Breast Cancer Cells Overexpressing This Oncogene”, Cancer Research 59, Mar. 15, 1999, pp. 1347-1355.
“Radiobiology/Radiation Oncology” Proceedings of the American Association for Cancer Research, Mar. 1996, vol. 37, p. 607.
Qian, et al., “Identification of p185neuSequences Required for Monoclonal Antibody- or Ligand-Medicated Receptor Signal Attenuation” DNA and Cell Bioloby, Mary Ann Liebert, Inc., vol. 16 No. 12, 1997, pp. 1395-1405.
Qian, et al. “Kinase-deficientneuproteins suppress epidermal growth factor receptor function and abolish cell transformation”, Oncogene (1994),9, pp. 1507-1514.
Raben, et al. “The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.”, Clin Cancer Res. Jan. 15, 2005(2 Pt 1): pp. 795-805. http://www.ncbi.nlm.nih.gov/entrea/query.fcgi?cmd=Retrieve&db=pubmed&dopt-abstract...(May 31, 2006).
Tsai, et al. “Enhanced Chemoresistance by Elevation of p185neuLevels in HER-2
eu-Transfected Human Lung Cancer Cells”, Journal of the National Cancer Institute, vol. 87, No. 9, May 1995, pp. 682-684.
Ueno et al., “Chemosensitization on HER-2
eu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5E1A”, Oncogene (1997) 15, pp. 953-960.
Webster, et al.,
Greene Mark I.
Murali Ramachandran
O'Rourke Donald M.
Park Byeong-Woo
Cooper & Dunham LLP
The Trustees of the University of Pennsylvania
White John P.
Yaen Christopher H
LandOfFree
Compositions and methods of treating tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods of treating tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods of treating tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4079973